SCHEMBL372265

SCHEMBL372265

C=CC(OC(C)C)OC(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL372314 0.85
SCHEMBL29025516 0.75
SCHEMBL28991351 0.73
SCHEMBL10593884 0.73
SCHEMBL674162 0.69
SCHEMBL10575183 0.67
SCHEMBL2458962 0.67
Ethylene SCHEMBL19987895 0.65
SCHEMBL243362 0.65
SCHEMBL76624 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1197870-C Preparation method and intermediate of erythromycin derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2005-04-20 CN claimed
US-6713615-B2 Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US claimed
US-20030191295-A1 Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-10-09 US claimed
CN-1446224-A Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2003-10-01 CN claimed
EP-1310506-A1 PROCESS FOR PRODUCING ERYTHROMYCIN DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-05-14 EP claimed
EP-2261212-B1 Preparation of quinoline-substituted carbamate derivatives ABBVIE INC (US) 2016-08-31 EP disclosed
EP-2409964-B1 Process for the preparation of carbonate derivatives ABBOTT LAB (US) 2016-01-27 EP disclosed
EP-1192139-B1 Preparation of quinoline-substituted carbonate and carbamate derivatives ABBOTT LAB (US) 2012-04-18 EP disclosed
EP-2409964-A2 Preparation of substituted carbonate and carbamate derivatives Abbott Laboratories (US) 2012-01-25 EP disclosed
EP-2261212-A2 Preparation of quinoline-substituted carbonate and carbamate derivatives Abbott Laboratories (US) 2010-12-15 EP disclosed
US-7074932-B2 Preparation of quinoline-substituted carbonate and carbamate derivatives ABBVIE INC. 2006-07-11 US disclosed
US-20060128962-A1 Preparation of quinoline-substituted carbonate and carbamate derivatives ALLEN MICHAEL S 2006-06-15 US disclosed
CN-1446224-A Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2003-10-01 CN disclosed
US-6579986-B2 Metal-catalyzed coupling reactions for 6-o-substituted macrolide antibiotics ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1310506-A1 PROCESS FOR PRODUCING ERYTHROMYCIN DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-05-14 EP disclosed
US-20020165390-A1 Preparation of quinoline-substituted carbonate and carbamate derivatives ABBVIE INC. 2002-11-07 US disclosed
US-6417366-B2 CHEMICAL INTERMEDIATE FOR MACROLACTONE ANTIBIOTIC ABBOTT LABORATORIES 2002-07-09 US disclosed
EP-1192139-A1 PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES Abbott Laboratories (US) 2002-04-03 EP disclosed
US-20020013468-A1 Preparation of quinoline-substituted carbonate and carbamate derivatives ABBVIE INC. 2002-01-31 US disclosed
WO-2001000582-A1 PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES ABBOTT LABORATORIES (US) 2001-01-04 WO disclosed